1. Home
  2. GRFS vs DLB Comparison

GRFS vs DLB Comparison

Compare GRFS & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • DLB
  • Stock Information
  • Founded
  • GRFS 1940
  • DLB 1965
  • Country
  • GRFS Spain
  • DLB United States
  • Employees
  • GRFS N/A
  • DLB N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • DLB Multi-Sector Companies
  • Sector
  • GRFS Health Care
  • DLB Miscellaneous
  • Exchange
  • GRFS Nasdaq
  • DLB Nasdaq
  • Market Cap
  • GRFS 6.6B
  • DLB 7.4B
  • IPO Year
  • GRFS 2006
  • DLB 2005
  • Fundamental
  • Price
  • GRFS $9.11
  • DLB $64.88
  • Analyst Decision
  • GRFS Hold
  • DLB Strong Buy
  • Analyst Count
  • GRFS 1
  • DLB 5
  • Target Price
  • GRFS $10.30
  • DLB $96.60
  • AVG Volume (30 Days)
  • GRFS 592.2K
  • DLB 481.0K
  • Earning Date
  • GRFS 01-01-0001
  • DLB 11-18-2025
  • Dividend Yield
  • GRFS 1.58%
  • DLB 2.03%
  • EPS Growth
  • GRFS 132.60
  • DLB 24.38
  • EPS
  • GRFS 0.53
  • DLB 2.71
  • Revenue
  • GRFS $8,744,226,659.00
  • DLB $1,346,912,000.00
  • Revenue This Year
  • GRFS $5.46
  • DLB $6.77
  • Revenue Next Year
  • GRFS $6.69
  • DLB $4.41
  • P/E Ratio
  • GRFS $22.60
  • DLB $23.95
  • Revenue Growth
  • GRFS 9.32
  • DLB 6.94
  • 52 Week Low
  • GRFS $6.19
  • DLB $64.50
  • 52 Week High
  • GRFS $11.14
  • DLB $89.66
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 36.85
  • DLB 32.16
  • Support Level
  • GRFS $9.14
  • DLB $64.50
  • Resistance Level
  • GRFS $9.50
  • DLB $66.59
  • Average True Range (ATR)
  • GRFS 0.29
  • DLB 1.27
  • MACD
  • GRFS -0.02
  • DLB -0.16
  • Stochastic Oscillator
  • GRFS 26.39
  • DLB 7.22

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About DLB Dolby Laboratories

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.

Share on Social Networks: